Venous Return Pressure Gradient as a Predictor of Acute Kidney Injury (VRPG-AKI)
Venous Return Pressure Gradient Predicts Acute Kidney Injury Onset and Progression
Acute kidney injury (AKI) is a common and serious complication in the ICU. Current diagnostic indicators (such as creatinine and urine output) exhibit significant lag, and specific hemodynamic predictive markers are lacking. The venous return pressure gradient (Pmsf-CVP), based on Guyton's theory, reflects the driving pressure for venous return; however, its value in the early warning of AKI remains unclear. This study aims to investigate the predictive value of the venous return pressure gradient for the onset and progression of AKI in ICU patients, and to clarify its effectiveness as an AKI risk warning indicator.
Patients admitted to the ICU within 48 hours with risk factors for AKI (including sepsis, shock, major surgery, underlying diseases, etc.) who have radial artery catheterization and can undergo hemodynamic monitoring will be enrolled. Those undergoing maintenance dialysis/CRRT, ECMO support, or with missing core data precluding calculation of Pmsf-CVP or AKI assessment will be excluded.
The venous return pressure gradient (Pmsf-CVP, mmHg) will be measured within 48 hours of ICU admission using the transient stop-flow arm arterial-venous equilibrium pressure method. The primary outcome is to evaluate the association between the venous return pressure gradient level and AKI occurrence. Secondary outcomes include correlation analyses between the venous return pressure gradient level and serum creatinine and urine output within 48 hours of ICU admission, among others.
調査の概要
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:rongan Liu
- 電話番号:+8615928731511
- メール:35279240@qq.com
研究連絡先のバックアップ
- 名前:chunling Chen
- 電話番号:+8618349304972
- メール:cclblingk@163.com
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Age ≥18 years
- Admitted to the intensive care unit (ICU) within 48 hours
- Central venous catheter in place for continuous central venous pressure (CVP) monitoring
- Radial artery catheter in place for hemodynamic monitoring including mean systemic filling pressure (Pmsf)
- No acute kidney injury (AKI) at ICU admission according to KDIGO criteria
Exclusion Criteria:
- Maintenance hemodialysis or continuous renal replacement therapy (CRRT) prior to ICU admission
- Previous kidney transplantation
- Pregnancy
- Extracorporeal membrane oxygenation (ECMO) support at ICU admission
- Incomplete core hemodynamic data precluding calculation of venous return pressure gradient (Pmsf-CVP) or AKI assessment
研究計画
研究はどのように設計されていますか?
デザインの詳細
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Acute Kidney Injury occurrence
時間枠:Within 48 hours of ICU admission
|
Occurrence of acute kidney injury diagnosed according to KDIGO criteria (serum creatinine increase ≥1.5 times baseline, or ≥26 μmol/L within 48 hours, or urine output <0.5 mL/kg/h for ≥6 hours) during the ICU stay.
The association between venous return pressure gradient (Pmsf-CVP, measured within the first 48 hours of ICU admission using the Pmsf-arm method) and AKI occurrence will be assessed by multivariable logistic regression analysis, adjusting for APACHE II score, baseline serum creatinine, lactate, mean arterial pressure, sepsis, and shock.
|
Within 48 hours of ICU admission
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Persistent Acute Kidney Injury
時間枠:Within 48 hours after AKI occurrence during the ICU stay
|
Persistent AKI defined as failure of renal function to return to baseline within 48 hours after AKI occurrence during the ICU stay.
The predictive value of venous return pressure gradient (Pmsf-CVP) for persistent AKI will be evaluated by ROC curve analysis.
|
Within 48 hours after AKI occurrence during the ICU stay
|
|
AKI severity grade
時間枠:At the time of maximum AKI stage during the ICU stay, up to 28 days
|
Maximum AKI stage (KDIGO stage 1, 2, or 3) achieved during the ICU stay.
|
At the time of maximum AKI stage during the ICU stay, up to 28 days
|
|
In-hospital mortality
時間枠:From ICU admission to hospital discharge, up to 90 days
|
All-cause mortality during the index hospitalization.
|
From ICU admission to hospital discharge, up to 90 days
|
|
Total length of hospital stay
時間枠:From hospital admission to discharge or death, up to 90 days
|
Number of days from hospital admission to hospital discharge or in-hospital death, whichever comes first.
Patients still hospitalized at day 90 will be censored at 90 days.
|
From hospital admission to discharge or death, up to 90 days
|
|
Correlation between venous return pressure gradient and serum creatinine
時間枠:Within 48 hours of ICU admission
|
Spearman rank correlation analysis between Pmsf-CVP (measured within 48 hours of ICU admission) and serum creatinine levels (baseline creatinine at ICU admission and peak creatinine during ICU stay).
|
Within 48 hours of ICU admission
|
|
Correlation between venous return pressure gradient and lactate
時間枠:Within 48 hours of ICU admission
|
Spearman rank correlation analysis between Pmsf-CVP (measured within 48 hours of ICU admission) and lactate levels obtained from the first arterial blood gas analysis within 48 hours of ICU admission.
|
Within 48 hours of ICU admission
|
|
Duration of mechanical ventilation
時間枠:From intubation to first successful extubation
|
Number of days on invasive mechanical ventilation from the time of first intubation to the first successful extubation.
Reintubation within 48 hours will be counted as continuous ventilation.
|
From intubation to first successful extubation
|
|
Length of ICU stay
時間枠:From ICU admission to ICU discharge
|
Number of days from ICU admission to ICU discharge.
|
From ICU admission to ICU discharge
|
協力者と研究者
出版物と役立つリンク
一般刊行物
- Asfar P, Meziani F, Hamel JF, Grelon F, Megarbane B, Anguel N, Mira JP, Dequin PF, Gergaud S, Weiss N, Legay F, Le Tulzo Y, Conrad M, Robert R, Gonzalez F, Guitton C, Tamion F, Tonnelier JM, Guezennec P, Van Der Linden T, Vieillard-Baron A, Mariotte E, Pradel G, Lesieur O, Ricard JD, Herve F, du Cheyron D, Guerin C, Mercat A, Teboul JL, Radermacher P; SEPSISPAM Investigators. High versus low blood-pressure target in patients with septic shock. N Engl J Med. 2014 Apr 24;370(17):1583-93. doi: 10.1056/NEJMoa1312173. Epub 2014 Mar 18.
- Boyd JH, Forbes J, Nakada TA, Walley KR, Russell JA. Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med. 2011 Feb;39(2):259-65. doi: 10.1097/CCM.0b013e3181feeb15.
- Hoste EA, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, Edipidis K, Forni LG, Gomersall CD, Govil D, Honore PM, Joannes-Boyau O, Joannidis M, Korhonen AM, Lavrentieva A, Mehta RL, Palevsky P, Roessler E, Ronco C, Uchino S, Vazquez JA, Vidal Andrade E, Webb S, Kellum JA. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015 Aug;41(8):1411-23. doi: 10.1007/s00134-015-3934-7. Epub 2015 Jul 11.
- Eskesen TG, Wetterslev M, Perner A. Systematic review including re-analyses of 1148 individual data sets of central venous pressure as a predictor of fluid responsiveness. Intensive Care Med. 2016 Mar;42(3):324-332. doi: 10.1007/s00134-015-4168-4. Epub 2015 Dec 9.
- Magder S. The use of Guyton's approach to the control of cardiac output for clinical fluid management. Ann Intensive Care. 2024 Jul 4;14(1):105. doi: 10.1186/s13613-024-01316-z.
- Chen X, Wang X, Honore PM, Spapen HD, Liu D. Renal failure in critically ill patients, beware of applying (central venous) pressure on the kidney. Ann Intensive Care. 2018 Sep 20;8(1):91. doi: 10.1186/s13613-018-0439-x.
- Badin J, Boulain T, Ehrmann S, Skarzynski M, Bretagnol A, Buret J, Benzekri-Lefevre D, Mercier E, Runge I, Garot D, Mathonnet A, Dequin PF, Perrotin D. Relation between mean arterial pressure and renal function in the early phase of shock: a prospective, explorative cohort study. Crit Care. 2011;15(3):R135. doi: 10.1186/cc10253. Epub 2011 Jun 6.
- Wonnacott A, Meran S, Amphlett B, Talabani B, Phillips A. Epidemiology and outcomes in community-acquired versus hospital-acquired AKI. Clin J Am Soc Nephrol. 2014 Jun 6;9(6):1007-14. doi: 10.2215/CJN.07920713. Epub 2014 Mar 27.
- Turgut F, Awad AS, Abdel-Rahman EM. Acute Kidney Injury: Medical Causes and Pathogenesis. J Clin Med. 2023 Jan 3;12(1):375. doi: 10.3390/jcm12010375.
- Rossiter A, La A, Koyner JL, Forni LG. New biomarkers in acute kidney injury. Crit Rev Clin Lab Sci. 2024 Jan;61(1):23-44. doi: 10.1080/10408363.2023.2242481. Epub 2023 Sep 5.
- Siew ED, Davenport A. The growth of acute kidney injury: a rising tide or just closer attention to detail? Kidney Int. 2015 Jan;87(1):46-61. doi: 10.1038/ki.2014.293. Epub 2014 Sep 17.
- Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 2012 Mar;81(5):442-8. doi: 10.1038/ki.2011.379. Epub 2011 Nov 23.
- Cerda J, Kashani K, Ostermann M, Basu RK, Bell S, Cantaluppi V, Chakaravarthi R, Costa JM, Claure-Del Granado R, Macedo E, Rhee H, Srisawat N, Wu VC, Yang L, Mehta RL. The global epidemiology of acute kidney injury: challenges and opportunities. Nat Rev Nephrol. 2026 Mar;22(3):179-198. doi: 10.1038/s41581-025-01030-4. Epub 2025 Dec 5.
- Chen KP, Cavender S, Lee J, Feng M, Mark RG, Celi LA, Mukamal KJ, Danziger J. Peripheral Edema, Central Venous Pressure, and Risk of AKI in Critical Illness. Clin J Am Soc Nephrol. 2016 Apr 7;11(4):602-8. doi: 10.2215/CJN.08080715. Epub 2016 Jan 19.
- Goeddel LA, Hernandez M, Koffman L, Murphy Z, Khanna AK, Robich M, Whitman G, Zhou X, Bandeen-Roche K, Muschelli J 3rd, Parikh CR, Lima JAC, Crainiceanu CM, Brown C 4th, Faraday N. Fine-Mapping the Association of Acute Kidney Injury With Mean Arterial and Central Venous Pressures During Coronary Artery Bypass Surgery. Anesth Analg. 2025 Jun 1;140(6):1439-1449. doi: 10.1213/ANE.0000000000007500. Epub 2025 Apr 17.
- Bolanos G F, de Pastrana SL. [Classification, diagnostic criteria and some therapeutic considerations of the solitary thyroid nodulf (author's transl)]. Rev Invest Clin. 1976 Oct-Dec;28(4):341-5. No abstract available. Spanish.
- Cops J, Mullens W, Verbrugge FH, Swennen Q, De Moor B, Reynders C, Penders J, Achten R, Driessen A, Dendooven A, Rigo JM, Hansen D. Selective abdominal venous congestion induces adverse renal and hepatic morphological and functional alterations despite a preserved cardiac function. Sci Rep. 2018 Dec 10;8(1):17757. doi: 10.1038/s41598-018-36189-3.
- Magder S, Slobod D, Vieillard-Baron A. Physiological and clinical significance of mean circulatory and mean systemic filling pressure. Ann Intensive Care. 2025 Nov 24;15(1):187. doi: 10.1186/s13613-025-01595-0.
- Damman K, Navis G, Smilde TD, Voors AA, van der Bij W, van Veldhuisen DJ, Hillege HL. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail. 2007 Sep;9(9):872-8. doi: 10.1016/j.ejheart.2007.05.010. Epub 2007 Jun 22.
- Panwar R, McNicholas B, Teixeira JP, Kansal A. Renal perfusion pressure: role and implications in critical illness. Ann Intensive Care. 2025 Aug 8;15(1):115. doi: 10.1186/s13613-025-01535-y.
- Chen CY, Zhou Y, Wang P, Qi EY, Gu WJ. Elevated central venous pressure is associated with increased mortality and acute kidney injury in critically ill patients: a meta-analysis. Crit Care. 2020 Mar 5;24(1):80. doi: 10.1186/s13054-020-2770-5.
- Legrand M, Dupuis C, Simon C, Gayat E, Mateo J, Lukaszewicz AC, Payen D. Association between systemic hemodynamics and septic acute kidney injury in critically ill patients: a retrospective observational study. Crit Care. 2013 Nov 29;17(6):R278. doi: 10.1186/cc13133.
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- IRB No. 321 (2026)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。